Global Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In Vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Application, Non-Cancer Applications, Non-Invasive Prenatal Testing (NIPT), Organ Transplantation, Infectious Disease Testing), Clinical Application (Early Cancer Screening, Diagnosis, Therapy Selection, Treatment Monitoring, Prognosis and Recurrence Monitoring), Sample Type, (Blood, Urine, Saliva, Cerebrospinal Fluid, Others), Product (Kits & Reagents, Blood Collection Tubes, Devices or System), Specimen (Blood, Bone Marrow, Other Body Fluids), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories) - Industry Trends and Forecast to 2023 to 2030.
Circulating Tumor Cells (CTC) Liquid Biopsy Market Analysis and Size
The essential factors contributing to the growth of the circulating tumor cells (CTC) liquid biopsy market in the forecast period of 2023-2030 include the growing demand of circulating tumor cells (CTC) liquid biopsy because of their effectiveness, increasing prevalence of cancer due to various genetic disorders, increasing alcohol consumption, and lifestyle changes. Along with this, the rising utilization of CTC for patient screening for metastasis and preclinical studies of emerging cancer drugs is contributing in the market’s growth. In addition, introduction of nanotechnology for improving the sensitivity and efficiency of CTC isolation and detection, widespread adoption of CTC-based liquid biopsy for rapid recovery and the rising demand for minimally invasive (MI) diagnostic procedures are significantly boosting the market’s growth.
Data Bridge Market Research analyses that the circulating tumor cells (CTC) liquid biopsy market which was USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In Vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Application, Non-Cancer Applications, Non-Invasive Prenatal Testing (NIPT), Organ Transplantation, Infectious Disease Testing), Clinical Application (Early Cancer Screening, Diagnosis, Therapy Selection, Treatment Monitoring, Prognosis and Recurrence Monitoring), Sample Type, (Blood, Urine, Saliva, Cerebrospinal Fluid, Others), Product (Kits & Reagents, Blood Collection Tubes, Devices or System), Specimen (Blood, Bone Marrow, Other Body Fluids), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
QIAGEN (Germany), Bio-Techne (U.S.), Precision Medical Group, LLC. (U.S.), Aviva Systems Biological Corporation (U.S.), Biocept, Inc. (U.S.), Fluxion Biosciences, Inc. (U.S.), Greiner Bio-One International GmbH (Austria) , Ikonisys (U.S.), Miltenyi Biotec (Germany), IVDiagnostics (U.S.), BioFluidica (U.S.), Canopus Medical (Sweden), Biolidics Limited (Singapore), Creativ MicroTech, Inc. (U.S.), LungLife AI, Inc. (U.S.), Epic Sciences (U.S.), Rarecells Diagnostics (France), ScreenCell (France), Menarini Silicon Biosystems (U.S.).
|
|
Market Opportunities
|
|
Market Definition
The liquid biopsy is a type of non-invasive blood test which identifies circulating tumor cells and tumor DNA fragments which are released in the blood by primary tumors and metastatic sites. It is an alternative to surgical biopsy procedure, and it allows surgeon to detect cancer at a very early stage. The circulating tumor cells function as a seed of metastases. The patients who have developed solid tumors it is found in them. The detection and quantification of tumor cells in the blood of cancer patients is allowed by the testing of circulating tumor cells. There are various types of biological phenotypes of circulating tumor cells (CTCs) such as stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity and due to which, a phase of isolation-enrichment is required in their detection.
Global Circulating Tumor Cells (CTC) Liquid Biopsy Dynamics
Drivers
- Rising prevalence of cancer
The rising prevalence of different types of cancer is boosting the market’s growth. The increasing number of cancer cases across the world is fuelling the demand of liquid biopsy. Breast cancer was the most common cancer 2020 with 2.26 million cases and further lung cancer with 2.21 million cases. The rising prevalence of cancer can be reduced through early detection of cancer and appropriate treatment. Circulating cancer cells are suitable for developing preclinical models, particularly 3D organoid cultures, for use in drug screening, disease modelling, genome editing, and organoid biobanks, thus significantly driving the market’s growth.
- Awareness initiatives by global health organizations and government
The governments in various countries and global health organizations are spreading awareness about cancer and other growing diseases. National Cancer Control program of WHO, is a public health program aiming to reduce the growing number of cancer deaths and improve the life of cancer patients. Furthermore, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), initiated by the US Centers for Diseases and Prevention (CDC) in 1991, provides breast cancer screening and diagnosis for uninsured and low-income patients in the US every year. The rising awareness in people about the effects and necessity to cure the diseases is increasing the liquid biopsy tests and treatments further driving the market’s growth.
Opportunities
- Growth opportunities in emerging countries
The developing countries such as India, Brazil, Turkey, Russia, South Africa, China, South Korea are offering major growth opportunities for liquid biopsy market. The major factors owing to the growth of liquid biopsy market in developing economies include improving healthcare infrastructure, higher cancer prevalence, large patient population, increasing disposable income, and growing medical tourism. Thus, there are number of opportunities for the market’s growth.
- Increasing R&D associated with liquid biopsy
The new research and development in liquid biopsies have revolutionized several related technologies, clinical oncology, devising personalized therapeutic regimens, offering easy tumor sampling, continuous monitoring by repeated sampling, and screening for therapeutic resistance. The increasing research and development is further increasing the demand of liquid biopsy which further increases the market’s growth.
Restraints/Challenges
- The lower sensitivity of certain liquid biopsies
In liquid biopsies certain procedures are technically challenging such as Detecting ctDNA because the levels of ctDNA of any given cancer mutation can be very low in the plasma of a cancer patient, after treatment or surgery. ctDNA is not applicable to all cancers, some tumor types are bad ctDNA shedders such as gliomas and sarcomas, and acts as an hurdle for ctDNA profiling. The reason for low ctDNA levels is not clear but is considered to be associated with tumor vascularity, location or the blood-brain barrier. Thus, the lower sensitivity of certain liquid biopsies is a major challenge for the market’s growth.
- Unclear reimbursement scenario
Limited reimbursement (non-coverage for panel-based tests) restricts the growth of liquid biopsy testing. The guidelines of NCD proved favorable for approval of Foundation One’s genomic profiling assay, but there are possibilities that it can work against other companies developing NGS-panel tests under LDT scenario. Multigene NGS tests have not secured FDA approval or reimbursement coverage, it is up to Medicare Administrative Contractors (MACs) to approve coverage when a company seeks a local coverage determination (LCD) if multigene NGS tests have not secured FDA approval or reimbursement coverage. These unclear reimbursement scenarios will be creating an unfavorable situation for liquid biopsy market’s growth.
This circulating tumor cells (CTC) liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the circulating tumor cells (CTC) liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2021, Myriad Genetics, Inc. announced that it has presented the data at San Antonio Breast Cancer Symposium and highlighted the value of genetic testing in breast cancer treatment. This will help Myriad Genetics, Inc. to advance the launch of novel product in the market. This advancement will further fuel the growth of liquid biopsy market’s growth.
- In February 2021, Menarini Silicon Biosystems announced the launch of CellMag product line for manual enrichment and staining of circulating tumor cells. This has helped Menarini Silicon Biosystems to increase its product line and will significantly boosts the market’s growth.
Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope
The circulating tumor cells (CTC) liquid biopsy market is segmented on the basis of technology, application, clinical application, sample type, product, specimen and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Technology
- CTC Detection Methods
- CTC Enrichment Methods
- Ex Vivo Positive Selection
- Molecular (RNA)-Based Technologies
- Functional In Vitro Cell Invasion Assay
- Xenotransplantation Models
- Microchips
- Single Spiral Microchannel
- Negative Selection & Immunocytochemical Technologies
Application
- Cancer Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Cancers
- Non-Cancer Applications
- Non-Invasive Prenatal Testing (NIPT)
- Organ Transplantation
- Infectious Disease Testing
Clinical Application
- Early Cancer Screening
- Diagnosis
- Therapy Selection
- Treatment Monitoring
- Prognosis and Recurrence Monitoring
Sample Type
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
- Others
Product
- Kits & Reagents
- Blood Collection Tubes
- Devices or System
Specimen
- Blood
- Bone Marrow
- Other Body Fluids
End User
- Research & Academic Institutes
- Reference Laboratories
- Hospitals
- Physician Laboratories
Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Regional Analysis/Insights
The circulating tumor cells (CTC) liquid biopsy market is analysed and market size insights and trends are provided, technology, application, clinical application, sample type, product, specimen and end user as referenced above.
The countries covered in the circulating tumor cells (CTC) liquid biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates global circulating tumor cells (CTC) liquid biopsy market. This is majorly due to the growing adoption of the liquid biopsy in the North American region for diagnosis of cancer. There are rapidly growing cases of cancer in US which has contributed in the dominance of North America in the global liquid biopsy market.
Asia Pacific is expected to grow during the forecast period of 2023 to 2030. The major factors contributing for the growth of the market in include Asia Pacific the increasing disposable income, rising awareness regarding the liquid biopsy techniques, and rising adoption of the advanced techniques in the hospitals, clinics, diagnostic laboratories for the diagnosis and increasing healthcare expenditure. In addition, the increasing penetration of hospitals and diagnostic centers are further boosting the market’s growth in the Asia Pacific region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Share Analysis
The circulating tumor cells (CTC) liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to circulating tumor cells (CTC) liquid biopsy market.
Some of the major players operating in the circulating tumor cells (CTC) liquid biopsy market are:
- QIAGEN (Germany)
- Bio-Techne (U.S.)
- Precision Medical Group, LLC. (U.S.)
- Aviva Systems Biological Corporation (U.S.)
- Biocept, Inc. (U.S.)
- Fluxion Biosciences, Inc. (U.S.)
- Greiner Bio-One International GmbH (Austria)
- Ikonisys (U.S.)
- Miltenyi Biotec (Germany)
- IVDiagnostics (U.S.)
- BioFluidica (U.S.)
- Canopus Medical (Sweden)
- Biolidics Limited (Singapore)
- Creativ MicroTech, Inc. (U.S.)
- LungLife AI, Inc. (U.S.)
- Epic Sciences (U.S.)
- Rarecells Diagnostics (France)
- ScreenCell (France)
- Menarini Silicon Biosystems (U.S.)
SKU-